Peritoneal Cancer-Pipeline Review, H1 2017

Peritoneal Cancer-Pipeline Review, H1 2017


  • Products Id :- GMDHC9208IDB
  • |
  • Pages: 759
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Peritoneal Cancer-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peritoneal Cancer-Pipeline Review, H1 2017, provides an overview of the Peritoneal Cancer (Oncology) pipeline landscape.

Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peritoneal Cancer-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Peritoneal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 12, 60, 36, 11, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 4 and 1 molecules, respectively.

Peritoneal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Peritoneal Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Peritoneal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Peritoneal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Peritoneal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Peritoneal Cancer (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Peritoneal Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Peritoneal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 6

Peritoneal Cancer-Overview 7

Peritoneal Cancer-Therapeutics Development 8

Peritoneal Cancer-Therapeutics Assessment 24

Peritoneal Cancer-Companies Involved in Therapeutics Development 40

Peritoneal Cancer-Drug Profiles 82

Peritoneal Cancer-Dormant Projects 734

Peritoneal Cancer-Discontinued Products 737

Peritoneal Cancer-Product Development Milestones 738

Appendix 745

List of Figures

Number of Products under Development for Peritoneal Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Peritoneal Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Peritoneal Cancer-Pipeline by 3-V Biosciences Inc, H1 2017

Peritoneal Cancer-Pipeline by AbbVie Inc, H1 2017

Peritoneal Cancer-Pipeline by Adaptimmune Therapeutics Plc, H1 2017

Peritoneal Cancer-Pipeline by Aduro BioTech Inc, H1 2017

Peritoneal Cancer-Pipeline by Advenchen Laboratories LLC, H1 2017

Peritoneal Cancer-Pipeline by Altor BioScience Corp, H1 2017

Peritoneal Cancer-Pipeline by Amgen Inc, H1 2017

Peritoneal Cancer-Pipeline by Arrien Pharmaceuticals LLC, H1 2017

Peritoneal Cancer-Pipeline by Astellas Pharma Inc, H1 2017

Peritoneal Cancer-Pipeline by Astex Pharmaceuticals Inc, H1 2017

Peritoneal Cancer-Pipeline by AstraZeneca Plc, H1 2017

Peritoneal Cancer-Pipeline by Atara Biotherapeutics Inc, H1 2017

Peritoneal Cancer-Pipeline by AVEO Pharmaceuticals Inc, H1 2017

Peritoneal Cancer-Pipeline by Bayer AG, H1 2017

Peritoneal Cancer-Pipeline by BeiGene Ltd, H1 2017

Peritoneal Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Peritoneal Cancer-Pipeline by Boston Biomedical Inc, H1 2017

Peritoneal Cancer-Pipeline by Bristol-Myers Squibb Company, H1 2017

Peritoneal Cancer-Pipeline by Celgene Corp, H1 2017

Peritoneal Cancer-Pipeline by Celldex Therapeutics Inc, H1 2017

Peritoneal Cancer-Pipeline by Celsion Corp, H1 2017

Peritoneal Cancer-Pipeline by CerRx Inc, H1 2017

Peritoneal Cancer-Pipeline by Clovis Oncology Inc, H1 2017

Peritoneal Cancer-Pipeline by Critical Outcome Technologies Inc, H1 2017

Peritoneal Cancer-Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017

Peritoneal Cancer-Pipeline by Eisai Co Ltd, H1 2017

Peritoneal Cancer-Pipeline by Eli Lilly and Company, H1 2017

Peritoneal Cancer-Pipeline by EpiThany Inc, H1 2017

Peritoneal Cancer-Pipeline by Esperance Pharmaceuticals Inc, H1 2017

Peritoneal Cancer-Pipeline by Exelixis Inc, H1 2017

Peritoneal Cancer-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Peritoneal Cancer-Pipeline by Galena Biopharma Inc, H1 2017

Peritoneal Cancer-Pipeline by Gene Techno Science Co Ltd, H1 2017

Peritoneal Cancer-Pipeline by Genelux Corp, H1 2017

Peritoneal Cancer-Pipeline by Genentech Inc, H1 2017

Peritoneal Cancer-Pipeline by Genor BioPharma Co Ltd, H1 2017

Peritoneal Cancer-Pipeline by Glycotope GmbH, H1 2017

Peritoneal Cancer-Pipeline by Gradalis Inc, H1 2017

Peritoneal Cancer-Pipeline by Hemispherx Biopharma Inc, H1 2017

Peritoneal Cancer-Pipeline by ImmunoGen Inc, H1 2017

Peritoneal Cancer-Pipeline by Immunovaccine Inc, H1 2017

Peritoneal Cancer-Pipeline by Incyte Corp, H1 2017

Peritoneal Cancer-Pipeline by Innate Pharma SA, H1 2017

Peritoneal Cancer-Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Peritoneal Cancer-Pipeline by Johnson & Johnson, H1 2017

Peritoneal Cancer-Pipeline by Juno Therapeutics Inc, H1 2017

Peritoneal Cancer-Pipeline by Lidds AB, H1 2017

Peritoneal Cancer-Pipeline by Mabion SA, H1 2017

Peritoneal Cancer-Pipeline by MabVax Therapeutics Holdings Inc, H1 2017

Peritoneal Cancer-Pipeline by Mateon Therapeutics Inc, H1 2017

Peritoneal Cancer-Pipeline by MedImmune LLC, H1 2017

Peritoneal Cancer-Pipeline by Medivir AB, H1 2017

Peritoneal Cancer-Pipeline by Merck & Co Inc, H1 2017

Peritoneal Cancer-Pipeline by Merck KGaA, H1 2017

Peritoneal Cancer-Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Peritoneal Cancer-Pipeline by MolMed SpA, H1 2017

Peritoneal Cancer-Pipeline by Mycenax Biotech Inc, H1 2017

Peritoneal Cancer-Pipeline by NewLink Genetics Corp, H1 2017

Peritoneal Cancer-Pipeline by Novartis AG, H1 2017

Peritoneal Cancer-Pipeline by Novogen Ltd, H1 2017

Peritoneal Cancer-Pipeline by Oasmia Pharmaceutical AB, H1 2017

Peritoneal Cancer-Pipeline by OBI Pharma Inc, H1 2017

Peritoneal Cancer-Pipeline by Oncobiologics Inc, H1 2017

Peritoneal Cancer-Pipeline by Oncolix Inc, H1 2017

Peritoneal Cancer-Pipeline by Oncolytics Biotech Inc, H1 2017

Peritoneal Cancer-Pipeline by OncoMed Pharmaceuticals Inc, H1 2017

Peritoneal Cancer-Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Peritoneal Cancer-Pipeline by Oxford BioMedica Plc, H1 2017

Peritoneal Cancer-Pipeline by Pfizer Inc, H1 2017

Peritoneal Cancer-Pipeline by Pharma Mar SA, H1 2017

Peritoneal Cancer-Pipeline by Polaris Pharmaceuticals Inc, H1 2017

Peritoneal Cancer-Pipeline by PsiOxus Therapeutics Ltd, H1 2017

Peritoneal Cancer-Pipeline by Richter Gedeon Nyrt, H1 2017

Peritoneal Cancer-Pipeline by Samyang Holdings Corp, H1 2017

Peritoneal Cancer-Pipeline by Sanofi, H1 2017

Peritoneal Cancer-Pipeline by Sanofi Pasteur SA, H1 2017

Peritoneal Cancer-Pipeline by Sotio AS, H1 2017

Peritoneal Cancer-Pipeline by Syndax Pharmaceuticals Inc, H1 2017

Peritoneal Cancer-Pipeline by TapImmune Inc, H1 2017

Peritoneal Cancer-Pipeline by Tyrogenex Inc, H1 2017

Peritoneal Cancer-Pipeline by Vascular Biogenics Ltd, H1 2017

Peritoneal Cancer-Pipeline by VentiRx Pharmaceuticals Inc, H1 2017

Peritoneal Cancer-Pipeline by Verastem Inc, H1 2017

Peritoneal Cancer-Dormant Projects, H1 2017

Peritoneal Cancer-Dormant Projects, H1 2017 (Contd..1), H1 2017

Peritoneal Cancer-Dormant Projects, H1 2017 (Contd..2), H1 2017

Peritoneal Cancer-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3-V Biosciences Inc, AbbVie Inc, Adaptimmune Therapeutics Plc, Aduro BioTech Inc, Advenchen Laboratories LLC, Altor BioScience Corp, Amgen Inc, Arrien Pharmaceuticals LLC, Astellas Pharma Inc, Astex Pharmaceuticals Inc, AstraZeneca Plc, Atara Biotherapeutics Inc, AVEO Pharmaceuticals Inc, Bayer AG, BeiGene Ltd, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corp, Celldex Therapeutics Inc, Celsion Corp, CerRx Inc, Clovis Oncology Inc, Critical Outcome Technologies Inc, Dr. Reddy's Laboratories Ltd, Eisai Co Ltd, Eli Lilly and Company, EpiThany Inc, Esperance Pharmaceuticals Inc, Exelixis Inc, F. Hoffmann-La Roche Ltd, Galena Biopharma Inc, Gene Techno Science Co Ltd, Genelux Corp, Genentech Inc, Genor BioPharma Co Ltd, Glycotope GmbH, Gradalis Inc, Hemispherx Biopharma Inc, ImmunoGen Inc, Immunovaccine Inc, Incyte Corp, Innate Pharma SA, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, Juno Therapeutics Inc, Lidds AB, Mabion SA, MabVax Therapeutics Holdings Inc, Mateon Therapeutics Inc, MedImmune LLC, Medivir AB, Merck & Co Inc, Merck KGaA, Millennium Pharmaceuticals Inc, MolMed SpA, Mycenax Biotech Inc, NewLink Genetics Corp, Novartis AG, Novogen Ltd, Oasmia Pharmaceutical AB, OBI Pharma Inc, Oncobiologics Inc, Oncolix Inc, Oncolytics Biotech Inc, OncoMed Pharmaceuticals Inc, Ono Pharmaceutical Co Ltd, Oxford BioMedica Plc, Pfizer Inc, Pharma Mar SA, Polaris Pharmaceuticals Inc, PsiOxus Therapeutics Ltd, Richter Gedeon Nyrt, Samyang Holdings Corp, Sanofi, Sanofi Pasteur SA, Sotio AS, Syndax Pharmaceuticals Inc, TapImmune Inc, Tyrogenex Inc, Vascular Biogenics Ltd, VentiRx Pharmaceuticals Inc, Verastem Inc

select a license

Single User License
USD 2000 INR 129880
Site License
USD 4000 INR 259760
Corporate User License
USD 6000 INR 389640

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com